Transition from Clinical Trials into RWE in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylarthritis
Communicate Baricitinib and Ixekizumab value proposition in a speaker program setting in order to communicate what the product may mean to people living with Rheumatoid Arthritis Psoriatic Arthritis and Ankylosing Spondylarthritis diseases

FREE
Free
16 Jul 2025 To 16 Jul 2025
09:00 PM To 10:30 PM
Certificate Available
Online Click Here